1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
- Read more in our News Archive
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
I have a male patient who takes Hydroxiurea from 5 years now due to sickle cell anemia (without this drug he was undergoing continuously to hemolityc crisis). he now wants a baby but his sperm is without cells. He stopped for 4 months hydroxiurea but no sign of recovery. It is possible that he became sterile?
Reproductive toxicity subsequent to hydroxyurea administration has been shown in male rats. Animal studies have shown alterations of sperm chromatin structure, abnormal sperm head morphology, decreased sperm density, and decreased circulating testosterone with hydroxyurea application. These effects are probably induced by the inhibition of ribonucleotide reductase and DNA synthesis leading to the depletion of meiotic daughter cells and differentiated cell types that normally produce mature sperm. Also apoptosis of germ cells appears to be increased by this agent. In human cases, a retrospective review of semen analysis from four adult men taking between 1 and 1.5 g/day of this medication for a period of 8 to 126 months, and from three of these men after cessation of therapy, it was suggested that hydroxyurea may reduce sperm count and motility and may results in abnormal morphology. One of these men with azoospermia, recovered from spermatogenesis upon the cessation of hydroxyurea treatment; however, in the other two cases sperm morphology and mobility remained impaired.